



RECEIVED 681615  
JUL 26 1999 CASE 4-20921B  
TECH CENTER 1800/2900

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen G. Kalinchak  
Type or print name

*Stephen G. Kalinchak*  
Signature

7/26/99  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

WAGNER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP97/03172

FILED: 18 JUNE 1997

U.S. APPLICATION NO: 09/202,805

35 USC §371 DATE: 7 MAY 1999

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP97/03172, copies are not enclosed herewith.


Also, copies of the other cited references are enclosed herewith.

Applicants provide the following statement of relevance for the non-English document "Innovatives Antihypertensives," Therapiewoche 36, pp. 1982-85 (1996). "Innovatives Antihypertensives" relates to innovative antihypertensives and angiotensin II antagonism as indicated by the title.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6763

  
Stephen G. Kalinchak  
Attorney for Applicants  
Reg. No. 38,747

Date: 7/20/99

RECEIVED  
JUL 26 1999  
TECH CENTER 1600/2800